Premium
Chemotherapy resistant transitional cell carcinoma as a target for chemoprevention
Author(s) -
Logothetis Christopher J.
Publication year - 1992
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.240501324
Subject(s) - fenretinide , chemotherapy , transitional cell carcinoma , refractory (planetary science) , medicine , malignancy , disease , oncology , carcinoma , interferon , cancer research , bladder cancer , immunology , cancer , cell culture , biology , retinoic acid , retinoid , astrobiology , genetics
Abstract α‐Interferon combined with 5‐fluorouracil results in significant antitumoral activity im metastatic bladder carcinoma refractory to standard MVAC chemotherapy. As a single agent, α‐interferon is ineffective for invasive ormetastatic diseasem, but appears to contribute to the increased response rate of patients with invasive chemotherapy‐refractory disease. Although most patinets with superficial bladder carcinoma will not develop invasive disease, patients in complete remission from invasive disease are at high risk for relapse. In vitro assays indicate that fenretinide (4‐HPR) line, α‐interferon, and 5‐fluorouracil posses significant antitumoral activity in human transitional cell carcinoma (TCC) lines. Some features of postchemotherapy‐refractory TCC are similar to those of initial superficial disease (senhsitivity to biological therapy). The biological study of patients with residual postchemotherapy disease may permit the development of strategies which will prevent the recurrence of malignancy within the bladder following an initial complete remission, in addition to developin strategies forthe selection and treatment of patients with high risk superficial disease. © 1992 Wiley‐Liss, Inc.